Randomised trial of four-drug vs less intensive two-drug chemotherapy in the palliative treatment of patients with small cell lung cancer (SCLC) and poor prognosis
1996

Chemotherapy for Small Cell Lung Cancer

publication

Author Information

Author(s): NM Bleehen, DJ Girling, P Hopwood, G Lallemand, D Machin, RJ Stephens, AJ Bailey

Primary Institution: Medical Research Council Lung Cancer Working Party

Conclusion

The corrected table shows the main adverse reactions reported by clinicians during the first three months of treatment.

Supporting Evidence

  • Alopecia was reported in 90% of patients receiving ECMV and 97% receiving EV.
  • Anorexia was reported in 48% of patients receiving ECMV and 43% receiving EV.
  • Nausea was reported in 61% of patients receiving ECMV and 48% receiving EV.
  • Vomiting was reported in 51% of patients receiving ECMV and 44% receiving EV.
  • Dysphagia was reported in 38% of patients receiving ECMV and 27% receiving EV.
  • Sore mouth/mucositis was reported in 54% of patients receiving ECMV and 34% receiving EV.
  • Numbness was reported in 38% of patients receiving ECMV and 35% receiving EV.
  • Haematological WHO grade 2 or worse was reported in 38% of patients receiving ECMV and 21% receiving EV.

Takeaway

Doctors looked at how patients felt after taking different cancer medicines, and they found some side effects that were more common with one type of medicine.

Statistical Information

Confidence Interval

0.77-1.35, 0.75-1.76, 0.98-2.09, 0.82-1.85, 0.86-2.34, 1.30-3.05, 0.73-1.85, 1.27-3.70, 1.11-3.52, 1.65-10.58, 0.46-11.45

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication